| Drug General Information |
| Drug ID |
D04ALU
|
| Former ID |
DIB018208
|
| Drug Name |
[3H](+)-cis-diltiazem
|
| Synonyms |
[3H]-(+)-cis-diltiazem
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
|
| Formula |
C22H26N2O4S
|
| InChI |
InChI=1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3
|
| InChIKey |
HSUGRBWQSSZJOP-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
4556838, 8151955, 10522522, 10589367, 11335179, 11360418, 11363138, 11365700, 11368262, 11374982, 11376424, 11461390, 11485548, 11489552, 11493076, 11494058, 14879942, 29222221, 47476379, 47550480, 47846442, 47995763, 50100216, 50100217, 50855580, 85245799, 85789652, 88977023, 103094892, 103154421, 104011325, 104302456, 104829104, 117600280, 118491175, 124960914, 125350387, 128108067, 135049062, 135265001, 135651160, 142577305, 143684696, 144239374, 162873103, 164808988, 174006614, 179039636, 184530473, 221672747
|
| Target and Pathway |
| Target(s) |
Voltage-dependent L-type calcium channel subunit alpha-1C |
Target Info |
Inhibitor (gating inhibitor) |
[2]
|
|---|
| Cav1.1 |
Target Info |
Inhibitor (gating inhibitor) |
[3]
|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Calcium signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
cAMP signaling pathway
|
|
Cardiac muscle contraction
|
|
Adrenergic signaling in cardiomyocytes
|
|
Vascular smooth muscle contraction
|
|
Circadian entrainment
|
|
Long-term potentiation
|
|
Retrograde endocannabinoid signaling
|
|
Glutamatergic synapse
|
|
Cholinergic synapse
|
|
Serotonergic synapse
|
|
GABAergic synapse
|
|
Dopaminergic synapse
|
|
Insulin secretion
|
|
GnRH signaling pathway
|
|
Oxytocin signaling pathway
|
|
Type II diabetes mellitus
|
|
Alzheimer's disease
|
|
Amphetamine addiction
|
|
Hypertrophic cardiomyopathy (HCM)
|
|
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
|
|
Dilated cardiomyopathy
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Alzheimer disease-amyloid secretase pathway
|
|
Nicotinic acetylcholine receptor signaling pathway
|
|
5HT2 type receptor mediated signaling pathway
|
|
Beta1 adrenergic receptor signaling pathway
|
|
Beta2 adrenergic receptor signaling pathway
|
|
Oxytocin receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathway
|
|
PathWhiz Pathway
|
Muscle/Heart Contraction
|
|
Reactome
|
Adrenaline,noradrenaline inhibits insulin secretion
|
|
NCAM1 interactions
|
|
Regulation of insulin secretion
|
|
WikiPathways
|
Calcium Regulation in the Cardiac Cell
|
|
Arrhythmogenic Right Ventricular Cardiomyopathy
|
|
Alzheimers Disease
|
|
NCAM signaling for neurite out-growth
|
|
Integration of energy metabolism
|
|
Nicotine Activity on Chromaffin Cells
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2512). |
|---|
| REF 2 | SR 33557, a novel calcium entry blocker. II. Interactions with 1,4-dihydropyridine, phenylalkylamine and benzothiazepine binding sites in rat heart sarcolemmal membranes. J Pharmacol Exp Ther. 1990 Nov;255(2):600-7. |
|---|
| REF 3 | High-affinity binding of DTZ323, a novel derivative of diltiazem, to rabbit skeletal muscle L-type Ca++ channels. J Pharmacol Exp Ther. 1997 Apr;281(1):173-9. |
|---|
